[0013] Also provided herein is a method of modulating the activity of SEQ ID NO. 1, wherein the modulation arises from a favorable conformation adopted by a compound, and wherein said modulation arises from a hydrogen bonding interaction between the compound and one, two, three or four of the following amino acids of SEQ ID NO.1: PRO124, THR126, GLU178 and SER180.

[0014] In another embodiment, a method of identifying a compound capable of binding to SEQ ID NO. 1 is provided, comprising: a) providing a molecular model comprising one or more target regions of SEQ ID NO. 1 derived from at least a portion of: SEQ ID NO. 1, atomic coordinates by molecular modeling of SEQ ID NO. 1, or atomic coordinates deposited in the Protein Data Bank under accession number 1PBQ; b) using the molecular model to identify a compound that can bind to the one or more target regions in the molecular model; and c) producing the compound. In some embodiments, such a method may further comprise the additional step of determining whether the compound modulates SEQ ID NO. 1.


[0015] Also provided herein are pharmaceutically acceptable compositions comprising a disclosed compound, and a pharmaceutically acceptable excipient. For example, such compositions may be suitable for oral administration to a patient.

[0016] A method for treating a cognitive disorder, such as a disorder associated with memory loss or impaired learning comprising administering to an patient in need thereof an effective amount of a disclosed compound. For example, provided herein are methods of treating or ameliorating memory loss or impaired learning in a patient in need thereof.

[0017] In an embodiment, methods for treating neuropathic pain in a patient in need thereof comprising administering an effective amount of a disclosed compound is provided.

[0018] Also disclosed herein are methods for treating depression, obsessive-compulsive disorder, or schizophrenia in a patient in need thereof comprising administering an effective amount of a disclosed compound. In another embodiment, methods for treating post traumatic stress disorder, an alcohol dependency disorder, or an addiction to an addictive drug in a patient in need thereof comprising administering an effective amount of a disclosed compounds are provided.


[0018a] Also disclosed herein is a compound represented by:




wherein

R^4 is H;

R^1 is benzyl;


R^5 is ,

R^6 is ;

R^2 is H or CH_3,

R^3 is H or CH_3, and stereoisomers, N-oxides or pharmaceutically acceptable salts thereof.


[0018b] Also disclosed herein is a compound represented by:




wherein

R^4 is H;


R^1 is H;

R^5 is ,


R^6 is ;

R^2 is CH_3 and R^3 is H; or R^2 is H and R^3 is CH_3; and stereoisomers, N-oxides or pharmaceutically acceptable salts thereof.

[0018c] Also disclosed herein is a compound represented by:



or



.


[0018d] Also disclosed herein is the use of a compound as described herein in the manufacture of a medicament for the treatment of a cognitive disorder associated with memory loss or impaired learning.

[0018e] Also disclosed herein is the use of a compound as described herein in the manufacture of a medicament for the treatment of neuropathic pain in a patient in need.

[0018f] Also disclosed herein is the use of a compound as described herein in the manufacture of a medicament for the treatment of depression, obsessive-compulsive disorder, or schizophrenia in a patient in need thereof.

Claims


1. A compound represented by:




wherein

R^4 is H;

R^1 is benzyl;

R^5 is ,

R^6 is ;


R^2 is H or CH_3,

R^3 is H or CH_3, and stereoisomers, N-oxides or pharmaceutically acceptable salts thereof.

2. The compound of claim 1, wherein R^2 and R^3 are CH_3.

3. The compound of claim 1, wherein R^2 is CH_3 and R^3 is H.


4. A compound represented by:




wherein

R^4 is H;

R^1 is H;


R^5 is ,




R^6 is ;

R^2 is CH_3 and R^3 is H; or R^2 is H and R^3 is CH_3; and stereoisomers, N-oxides or pharmaceutically acceptable salts thereof.

5. A compound represented by:



or



.

6. The use of a compound of any one of claims 1-5 in the manufacture of a medicament for the treatment of a cognitive disorder associated with memory loss or impaired learning.

7. A pharmaceutically acceptable composition comprising a compound of any one of claims 1-5, and a pharmaceutically acceptable excipient.

8. The use of a compound of any one of claims 1-5 in the manufacture of a medicament for the treatment of neuropathic pain in a patient in need.

9. The use of a compound of any one of claims 1-5 in the manufacture of a medicament for the treatment of depression, obsessive-compulsive disorder, or schizophrenia in a patient in need thereof.